|11th November 2020||Carl Goldfischer||5,000||Open or private purchase||$12.07||$60,350.00|
|16th March 2020||Carl Goldfischer||690,232||Conversion of derivative||$0.00|
|16th March 2020||Carl Goldfischer||13,148||Conversion of derivative||$0.00|
|10th October 2019||Sujal Shah||5,000||Open or private purchase||$4.30||$21,500.00|
|23rd September 2019||Sujal Shah||3,100||Open or private purchase||$5.55||$17,205.00|
|20th September 2019||Sujal Shah||1,900||Open or private purchase||$5.50||$10,450.00|
|7th February 2019||Carl Goldfischer||2,335||Exercise of derivative||$5.00||$11,675.00|
|7th February 2019||Carl Goldfischer||9,340||Exercise of derivative||$5.50||$51,370.00|
|7th February 2019||Carl Goldfischer||11,675||Open or private sale||$9.02||$105,328.35|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company. Its products include MBX-8025 and Arhalofenate. The company was founded on October 5, 1988 and is headquartered in Newark, CA.